Published in PLoS One on March 20, 2015
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med (2005) 12.18
Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors. Cell (1998) 4.00
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood (2008) 3.77
Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med (2008) 3.67
Differential expression of novel potential regulators in hematopoietic stem cells. PLoS Genet (2005) 3.11
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol (2008) 3.02
Conserved roles for Slit and Robo proteins in midline commissural axon guidance. Neuron (2004) 2.94
Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev Biol (2003) 2.58
Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52
Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics (2002) 2.21
Robo4 cooperates with CXCR4 to specify hematopoietic stem cell localization to bone marrow niches. Cell Stem Cell (2011) 1.98
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood (2009) 1.87
Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat Cell Biol (2009) 1.73
roundabout4 is essential for angiogenesis in vivo. Proc Natl Acad Sci U S A (2005) 1.69
Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis (2008) 1.64
Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res (2007) 1.61
RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol (2007) 1.61
Magic roundabout, a tumor endothelial marker: expression and signaling. Biochem Biophys Res Commun (2005) 1.59
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood (2011) 1.55
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol (2003) 1.47
DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood (2011) 1.44
In silico cloning of novel endothelial-specific genes. Genome Res (2000) 1.42
Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res (2006) 1.31
Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. Leukemia (2002) 1.23
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia (2013) 1.21
Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J (2014) 1.18
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia (2010) 1.17
Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet (1995) 1.10
Robo1/Robo4: differential expression of angiogenic markers in colorectal cancer. Oncol Rep (2006) 1.10
Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD. Leukemia (2007) 1.06
Identification of reference genes across physiological states for qRT-PCR through microarray meta-analysis. PLoS One (2011) 1.04
Roundabout 4 is expressed on hematopoietic stem cells and potentially involved in the niche-mediated regulation of the side population phenotype. Stem Cells (2009) 0.97
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am J Hematol (2013) 0.97
High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes. Br J Cancer (2011) 0.94
Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia (2006) 0.91
Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol (1994) 0.91
Correlation of spectral imaging and visual grading for the quantification of thymidylate synthase protein expression in rectal cancer. Hum Pathol (2005) 0.90
Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest (2000) 0.89
A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. Leukemia (2014) 0.88
Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. Haematologica (2010) 0.87
Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody. Blood (2013) 0.85
Serum levels of Magic Roundabout protein in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer (2005) 0.84
Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'. Br J Cancer (2009) 0.82
Robo4 plays a role in bone marrow homing and mobilization, but is not essential in the long-term repopulating capacity of hematopoietic stem cells. PLoS One (2012) 0.82
Stimulation of proliferation and differentiation of acute myeloid leukemia cells on a bone marrow stroma in culture. Exp Hematol (1985) 0.80
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood (2009) 1.87
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood (2016) 1.05
The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect. Blood (2010) 0.93
Extraocular well-differentiated sebaceous tumors with overlying cutaneous horns: four tumors in three patients. J Cutan Pathol (2014) 0.92
Improving but inferior survival in patients with chronic lymphocytic leukemia in taiwan: a population-based study, 1990-2004. PLoS One (2013) 0.84
Clinical characteristics and treatment outcomes of patients with candidaemia due to Candida parapsilosis sensu lato species at a medical centre in Taiwan, 2000-12. J Antimicrob Chemother (2015) 0.80
Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia. Oncotarget (2016) 0.79
Rapidly fatal leukemia comprising pleomorphic large granular lymphocytes: a report of 2 cases. Anal Quant Cytopathol Histpathol (2013) 0.79
Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. Oncotarget (2017) 0.77
High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. PLoS One (2015) 0.77
Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement. Int J Hematol (2014) 0.77
Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study. Hepatology (2016) 0.77
Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection. Ann Hematol (2016) 0.76
Expressions of the CagA protein and CagA-signaling molecules predict H. pylori-dependence of early-stage gastric DLBCL. Blood (2016) 0.76
Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). Oncotarget (2016) 0.75
Reduced incidence of interstitial pneumonitis after allogeneic hematopoietic stem cell transplantation using a modified technique of total body irradiation. Sci Rep (2016) 0.75
Multiple Giant Mushroom-like Tumors Inside the Stomach. Gastroenterology (2016) 0.75
The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model. J Hematol Oncol (2017) 0.75
Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas. Oncotarget (2017) 0.75
Clinicopathological analysis of primary central nervous system NK/T-cell lymphoma: rare and localised aggressive tumour among extranasal NK/T-cell tumours. Histopathology (2017) 0.75
Cervical Papanicolaou Smears in Hematopoietic Stem Cell Transplant Recipients: High Prevalence of Therapy-Related Atypia during the Acute Phase. Biol Blood Marrow Transplant (2017) 0.75
B cell-activating factor signalling pathway is associated with H. pylori independence in gastric MALT lymphoma without t(11;18)(q21;q21). J Pathol (2016) 0.75
Successful treatment of gestational trophoblastic neoplasia in the uterine cornus with laparoscopic cornuostomy and postoperative methotrexate injection. Taiwan J Obstet Gynecol (2017) 0.75
Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas. Oncotarget (2017) 0.75
Aurora A and NF-κB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA. Cancer Res (2016) 0.75
Similar epidemiological trends of pre-neoplastic precursors and their respective lymphoid malignancies in Taiwan. Ann Hematol (2016) 0.75
High expression of dedicator of cytokinesis 1 (DOCK1) confers poor prognosis in acute myeloid leukemia. Oncotarget (2017) 0.75